Tag: information

Please see below information about transactions made under the second tranche of the 2025 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO).

PRESS RELEASE

Amsterdam, July 1, 2025

AB “Ignitis grupė” (hereinafter – the Group) informs that on 30 June, with the agreement of the Group’s Management Board, the Group’s subsidiaries UAB “Ignitis renewables” (hereinafter – Ignitis Renewables) and AB “Ignitis gamyba” (hereinafter – Ignitis Gamyba) made final investment decisions on three battery energy storage system (hereinafter – BESS) projects in Lithuania, with a combined 291 MW power and 582 MWh storage capacity. The German company Rolls-Royce Solutions GmbH will provide the equipment and the integration services for all three BESS projects.

AB “Ignitis grupė” (hereinafter – the Group) informs that on 30 June, with the agreement of the Group’s Management Board, the Group’s subsidiaries UAB “Ignitis renewables” (hereinafter – Ignitis Renewables) and AB “Ignitis gamyba” (hereinafter – Ignitis Gamyba) made final investment decisions on three battery energy storage system (hereinafter – BESS) projects in Lithuania, with a combined 291 MW power and 582 MWh storage capacity. The German company Rolls-Royce Solutions GmbH will provide the equipment and the integration services for all three BESS projects.

EINDHOVEN, the Netherlands, July 01, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announced the submission of two major regulatory applications for its ARC-EX System. The Company has submitted a 510(k) application to the US Food and Drug Administration (FDA) seeking clearance to expand its indication for home use. In parallel, ONWARD has filed an application with the notified body for CE Mark certification in accordance with the European Union Medical Device Regulation (MDR) to enable commercialization of the ARC-EX System in the EU. Completed in June, these submissions represent significant milestones as the Company advances its mission to bring breakthrough therapies to people with SCI around the world.

Global non-profit Equalall has so far been involved in fundraising for and mobilizing life-saving aid for victims of war, displacement, and natural disasters in Gaza, Syria, Sudan

LAUSANNE, Switzerland and COPENHAGEN, Denmark, July 01, 2025 (GLOBE NEWSWIRE) -- ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women’s health, today announced that the first participant has been included in the company’s Phase 2 clinical trial of its lead candidate RPN-001 (leflutrozole), an orally administered aromatase inhibitor in development for the treatment of male infertility (https://clinicaltrials.gov/study/NCT06993155?term=Leflutrozole&rank=1).